Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JAZZ PHARMACEUTICALS PLC

(JAZZ)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/21/2021 07/22/2021 07/23/2021 07/26/2021 07/27/2021 Date
176.83(c) 173.82(c) 173.93(c) 173.26(c) 173.71(c) Last
531 944 420 424 327 045 341 356 317 887 Volume
+0.87% -1.70% +0.06% -0.39% +0.26% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 3 106 M - -
Net income 2021 -172 M - -
Net Debt 2021 5 461 M - -
P/E ratio 2021 -55,5x
Yield 2021 -
Sales 2022 3 828 M - -
Net income 2022 514 M - -
Net Debt 2022 4 653 M - -
P/E ratio 2022 13,0x
Yield 2022 -
Capitalization 10 592 M 10 592 M -
EV / Sales 2021 5,17x
EV / Sales 2022 3,98x
Nbr of Employees 1 940
Free-Float 97,5%
More Financials
Company
Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both... 
Sector
Pharmaceuticals
Calendar
07/29 | 10:00amShareholder meeting
More about the company
Ratings of Jazz Pharmaceuticals plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about JAZZ PHARMACEUTICALS PLC
07/23JAZZ PHARMACEUTICALS : RBC Boosts Price Target on Jazz Pharmaceuticals to $216 F..
MT
07/23JAZZ PHARMACEUTICALS : Rylaze Added to National Comprehensive Cancer Network Gui..
MT
07/22Jazz Pharmaceuticals plc Announces National Comprehensive Cancer Network Adds..
CI
07/22PAO GROUP, INC. INTENDS GET ITS FIRS : Paog)
AQ
07/22LIGAND PHARMACEUTICALS INCORPORATED : Partner jazz pharmaceuticals launches ryla..
AQ
07/21LIGAND PHARMACEUTICALS INCORPORATED : Pharma to Receive $7 Million in Milestone ..
MT
07/21Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia ch..
CI
07/20JAZZ PHARMACEUTICALS : Rylaze Investor Update
PU
07/20JAZZ PHARMACEUTICALS : to Report 2021 Second Quarter Financial Results on August..
PR
07/19JAZZ PHARMACEUTICALS : Financial Statements and Exhibits (form 8-K/A)
AQ
07/19AML Hub continues to enhance global knowledge of acute myeloid leukemia throu..
AQ
07/13JAZZ PHARMACEUTICALS : Announces Rylaze™ (asparaginase erwinia chrysanthem..
PR
07/07JAZZ PHARMACEUTICALS : Health Canada Approves Vyxeos®, the First Chemotherapy Ad..
AQ
07/07Health Canada Approves Jazz Pharmaceuticals plc 's Vyxeos®
CI
07/06Horizons ETFs Rebalances Marijuana-Focused Index Etfs
AQ
More news
News in other languages on JAZZ PHARMACEUTICALS PLC
07/06++ Analysen des Tages von Dow Jones Newswires (06.07.2021) +++
07/06HINTERGRUND/Bei Pharma-Übernahmen schlagen inzwischen oft Midcaps zu
05/28EQS-ADHOC : HBM-Portfoliounternehmen Swixx BioPharma kündigt Kapital-erhöhung vo..
03/29ORIGINAL-RESEARCH : Cardiol Therapeutics (von GBC AG): Research Watchlist
03/01Pharma Mar cierra un acuerdo de distribución de lurbinectedina en Latinoaméri..
More news
Analyst Recommendations on JAZZ PHARMACEUTICALS PLC
More recommendations
Chart JAZZ PHARMACEUTICALS PLC
Duration : Period :
Jazz Pharmaceuticals plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JAZZ PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 173,71 $
Average target price 210,35 $
Spread / Average Target 21,1%
EPS Revisions
Managers and Directors
Bruce C. Cozadd Chairman & Chief Executive Officer
Daniel N. Swisher President
Renée D. Galá Chief Financial Officer & Executive Vice President
Robert Iannone Chief Medical Officer, EVP-Research & Development
Finbar Larkin Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
JAZZ PHARMACEUTICALS PLC4.97%10 575
JOHNSON & JOHNSON9.21%452 602
ROCHE HOLDING AG11.50%327 852
PFIZER, INC.13.58%234 040
NOVARTIS AG-0.17%221 954
ELI LILLY AND COMPANY44.05%221 084